Clínic Barcelona

Begins a clinical trial of a new technique to treat Multiple Sclerosis and Neuromyelitis Optica

The Spanish Agency for Medicines and Health Products (AEMPS) has approved a clinical trial in humans with an Antigen-Specific therapy with dendritic cells, a pioneering technique for the treatment of Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) in a more effective way and with fewer side effects. Dr. Pablo Villoslada, head of the IDIBAPS group Pathogenesis and new treatments in multiple sclerosis, and Dr. Daniel Benitez, researcher at the Inflammatory bowel disease IDIBAPS team, coordinate this trial led by the Hospital Clinic and driven by the Multiple Sclerosis Affected Group Foundation (GAEM) and "la Caixa" Foundation.